Textbook of Personalized Medicine - Second Edition [2015]

135

Table 4.9 Pharmacogenomic biomarkers in drug labeling

Drug Therapeutic area Gene Referenced subgroup
Abacavir Infectious diseases HLA-B HLA-B*5701 allele
carriers
Ado-trastuzumab
emtansine

Oncology ERBB2 HER2 protein
overexpression or gene
amplifi cation positive
Afatinib Oncology EGFR EGFR exon 19 deletion or
exon 21 substitution
(L858R) mutation
positive
Amitriptyline Psychiatry CYP2D6 CYP2D6 poor metabolizers
Anastrozole Oncology ESR1, PGR Hormone receptor positive
Aripiprazole Psychiatry CYP2D6 CYP2D6 poor metabolizers
Arsenic trioxide Oncology PML/RARA PML/RARα (t(15;17))
gene expression positive
Atomoxetine Psychiatry CYP2D6 CYP2D6 poor metabolizers
Atorvastatin Endocrinology LDLR Homozygous familial
hypercholesterolemia
Azathioprine Rheumatology TPMT TPMT intermediate or poor
metabolizers
Belimumab Autoimmune
diseases

BAFF/TNFSF13B CD257 positive

Boceprevir Infectious diseases IFNL3 IL28B rs12979860 T allele
carriers
Bosutinib Oncology BCR/ABL1 Philadelphia chromosome
(t(9;22)) positive
Brentuximab Vedotin Oncology TNFRSF8 CD30 positive
Busulfan Oncology Ph Chromosome Ph Chromosome negative
(lack of effectiveness
with Ph positive)
Capecitabine Oncology DPYD DPD defi cient
Carbamazepine (1) Neurology HLA-B HLA-B1,502 allele
carriers
Carbamazepine (2) Neurology HLA-A HLA-A3,101 allele
carriers
Carglumic Acid Metabolic disorders NAGS N-acetylglutamate synthase
defi ciency
Carisoprodol Rheumatology CYP2C19 CYP2C19 poor
metabolizers
Carvedilol Cardiology CYP2D6 CYP2D6 poor metabolizers
Celecoxib Rheumatology CYP2C9 CYP2C9 poor metabolizers
Cetuximab (1) Oncology EGFR EGFR protein expression
positive
Cetuximab (2) Oncology KRAS KRAS codon 12 and 13
mutation negative
Cevimeline Dermatology CYP2D6 CYP2D6 poor metabolizers
Chloroquine Infectious diseases G6PD G6PD defi cient
(continued)

Clinical Implications of Pharmacogenetics